Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Amelia Tesone"'
Autor:
Melanie Rutkowski, Tom Stephen, Michael Allegrezza, Nikolaos Svoronos, Alfredo Perales-Puchalt, Amelia Tesone, Jenny Nguyen, Julia Tchou, Jose Conejo-Garcia
Publikováno v:
The Journal of Immunology. 192:133.4-133.4
The dominant R392X TLR5 polymorphism abrogates flagellin responses in >7% of humans. We report that TLR5 recognition of commensal bacteria at intestinal surfaces influences malignant progression at distal (extra-mucosal) locations through the initiat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cdc68de7b5e04696df22a115f0b5864
https://doi.org/10.4049/jimmunol.192.supp.133.4
https://doi.org/10.4049/jimmunol.192.supp.133.4
Autor:
Nikolaos Svoronos, Michael Allegrezza, Jenny Nguyen, Alfredo Perales-Puchalt, Melanie Rutkowski, Tom Stephen, Amelia Tesone, Jose Conejo-Garcia
Publikováno v:
The Journal of Immunology. 192:203.25-203.25
Estradiol is a pleiotropic steroid hormone that regulates homeostasis, cell growth, and the immune system. In estrogen receptor positive breast cancer, anti-estrogen therapies are used to inhibit tumor cell growth. However, estrogen receptor α is al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13ce85d96518f2e53a8cd028132147b7
https://doi.org/10.4049/jimmunol.192.supp.203.25
https://doi.org/10.4049/jimmunol.192.supp.203.25
Autor:
Michael Allegrezza, Melanie Rutkowski, Tom Stephen, Nikos Svoronos, Amelia Tesone, Jose Conejo-Garcia
Publikováno v:
The Journal of Immunology. 190:132.4-132.4
Much attention has been given to the idea of personalized cancer treatment, where the oncogenes driving tumor growth can be identified in each patient and targeted with specific molecular therapies. Many targeted inhibitors are in clinical developmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc76011c2afafe7cf2b1b9fda2b6b854
https://doi.org/10.4049/jimmunol.190.supp.132.4
https://doi.org/10.4049/jimmunol.190.supp.132.4
Autor:
Melanie Rutkowski, Ximena Escovar-Fadul, Fahmida Sarmin, Tom Stephen, Michael Allegrezza, Oswaldo Gil-Guerva, Amelia Tesone, Jose Conejo-Garcia
Publikováno v:
The Journal of Immunology. 188:162.48-162.48
It has been reported that up to 25% of the human population carries a dominant point mutation in TLR5 resulting in the loss of TLR5 signaling. TLR5 expression is paramount in modulating the balance of regulatory FoxP3+ and proinflamatory IL-17+ T cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b3b27d8c29ebf90c3fc0df8d96bf939
https://doi.org/10.4049/jimmunol.188.supp.162.48
https://doi.org/10.4049/jimmunol.188.supp.162.48